Francesco Buccisano

Also affiliated with Policlinico Tor Vergata

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations”.

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations

Leukemia(2021)10.1038/s41375-021-01230-4

N/A

0.659DataRank · unranked

80 citations

Yishai Ofran, Agnieszka Wierzbowska, Farhad Ravandi, Christopher S. Hourigan, Lok Lam Ngai +5 more

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood(2021)10.1182/blood.2021013626

N/A

0DataRank · unranked

738 citations

Sylvie Freeman, Gert J. Ossenkoppele, Francesco Buccisano, Christopher S. Hourigan, Lok Lam Ngai +40 more

Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel

American Journal of Hematology(2023)10.1002/ajh.27087

N/A

0DataRank · unranked

24 citations

Jacqueline Cloos, Francesco Buccisano, Richard Dillon, Konstanze Döhner, Sylvie Freeman +12 more

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Leukemia(2024)10.1038/s41375-024-02378-5

N/A

0DataRank · unranked

12 citations

Megan Othus, Sylvie Freeman, Francesco Buccisano, Lok Lam Ngai, Ian Thomas +11 more